akusherstvoObstetrics, Gynecology and ReproductionАкушерство, Гинекология и Репродукция2313-73472500-3194IRBIS LLC10.17749/2070-4968.2015.9.3.011-016akusherstvo-166Research ArticleОRIGINAL ARTICLESОРИГИНАЛЬНЫЕ СТАТЬИCLINICAL LABORATORY INDICATORS OF PREGNANT WITH ANTIPHOSPHOLIPID SYNDROME IN COMPLEX THERAPY WITH USING INTRAVENOUS IMMUNOGLOBULINКЛИНИКО-ЛАБОРАТОРНЫЕ ПОКАЗАТЕЛИ БЕРЕМЕННЫХ С АНТИФОСФОЛИПИДНЫМ СИНДРОМОМ ПРИ КОМПЛЕКСНОЙ ТЕРАПИИ С ПРИМЕНЕНИЕМ ВНУТРИВЕННОГО ИММУНОГЛОБУЛИНАЛинниковВ. И.LinnikovV. I.
д.м.н., профессор, научный консультант медико-генетического центра «ГерMедTех»
MD, professor, Senior scientific consultant, Medical Genetic Center «GerMedTech»
germedtech@gmail.comГородской центр планирования семьи и репродукции, Одесса, Украина,
Медико-генетический центр «ГерМедТех», Одесса, УкраинаРоссияCity Center for Family Planning and Reproduction, Odessa, Ukraine, Medical Genetics Center "GerMedTeh", Odessa, UkraineRussian Federation201519062016931116Copyright © Linnikov V.I., 20162016Линников В.И.Linnikov V.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gynecology.su/jour/article/view/166Антифосфолипидный синдромсистема гемостазасиндром потери плодавнутривенный иммуноглобулиниммунокомпетентные лимфоцитыAntiphospholipid syndromehemostasis systemfetal loss syndromeinravenous immunoglobulinimmunocompetent lymphocytesReferencesМакацария А.Д., Бицадзе В.О., Хизроева Д.Х., Макацария Н.А., Яшенина Е.В. Патогенетичес- кое значение антифосфолипидных антител. Практическая медицина. 2012; 5: 9-20.Makatsariya A.D., Bitsadze V.O., Khizroeva D.Kh., Makatsariya N.A., Yashenina E.V. Prakticheskaya meditsina. 2012; 5: 9-20.Макацария А.Д., Бицадзе В.О. Тромбофилия и противотромботическая терапия в акушерской практике. M. 2003; 904 с.Makatsariya A.D., Bitsadze V.O. Thrombophilia and antithrombotic therapy in obstetric practice [Trombofiliya i protivotromboticheskaya terapiya v akusherskoi praktike (in Russian)]. Moscow. 2003; 904 s.Макацария А.Д., Бицадзе В.О., Баймуратова С.М., Долгушина Н.В., Юдаева Л.С., Хизро- ева Д.Х., Акиньшина С.В. Антифосфолипид- ный синдром – иммунная тромбофилия в акушерстве и гинекологии. М. 2013; 485 с.Makatsariya A.D., Bitsadze V.O., Baimuratova S.M., Dolgushina N.V., Yudaeva L.S., Khizroeva D.Kh., Akin'shina S.V. Antiphospholipid syndrome – the immune thrombophilia in obstetrics and gynecology [Antifosfolipidnyi sindrom – immunnaya trombofiliya v akusherstve i ginekologii (in Russian)]. Moscow. 2013; 485 s.Сельков А.В., Селютин А.В. Методы опреде- ления содержания Т-регуляторных клеток в периферической крови. Лабораторная диагностика. 2008; 4: 19-21.Sel'kov A.V., Selyutin A.V. Laboratornaya diagnostika. 2008; 4: 19-21.Сидельникова В.М. Привычная потеря бере- менности. М. 2005; 304-307.Sidel'nikova V.M. The usual pregnancy loss [Privychnaya poterya beremennosti (in Russian)]. Moscow. 2005; 304-307.Ярилин А.А., Донецкова Ф.Д. Регуляторные Т-клетки, зависимые от фактора FOXp3, и перспективы их изучения при беремен- ности. Rus J. Immunol. 2005; 9: 149-152.Yarilin A.A., Donetskova F.D. Regulyatornye T-kletki, zavisimye ot faktora FOXp3, i perspektivy ikh izucheniya pri beremennosti. Rus J. Immunol. 2005; 9: 149-152.Branch D.W., Peaceman A.M., Silver R.K. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol. 2000; 182 (1): 122-127.Branch D.W., Peaceman A.M., Silver R.K. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol. 2000; 182 (1): 122-127.Carp H., Sapir T., Shoenfeld Y. Inravenous immunoglobulin and recurrent pregnancy loss. Clin. Rev. Allegy Immunol. 2005; 29 (3): 327-332.Carp H., Sapir T., Shoenfeld Y. Inravenous immunoglobulin and recurrent pregnancy loss. Clin. Rev. Allegy Immunol. 2005; 29 (3): 327-332.Coulam C.D., Roussev R.G. Correlation of NK cell activation and inhibition markers with NK cytoxicity among women experiencing immunologic implantation failure after in vitro ferilization and embryotransfer. J. Ass. Reprod. Genet. 2003; 20: 58-62.Coulam C.D., Roussev R.G. Correlation of NK cell activation and inhibition markers with NK cytoxicity among women experiencing immunologic implantation failure after in vitro ferilization and embryotransfer. J. Ass. Reprod. Genet. 2003; 20: 58-62.Guerin L.R. Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment? Human Reproduction Update. 2009; 15 (5): 535-571.Guerin L.R. Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment? Human Reproduction Update. 2009; 15 (5): 535-571.Chen M.L., Pittet M.J., Gorelik Regulatry I. T-cells suppress tumor-specific CD8 T-cell cytotoxity through TGF-b signals in vivo. Proc. Nath. Acaci. Sci USA. 2005; 102: 409-424.Chen M.L., Pittet M.J., Gorelik Regulatry I. T-cells suppress tumor-specific CD8 T-cell cytotoxity through TGF-b signals in vivo. Proc. Nath. Acaci. Sci USA. 2005; 102: 409-424.Christiansen O.D. A randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarnage evidence for a therapeutic effect in women with secondry recurrent miscamage. Hum. Reprod. 2002; 17: 809-816.Christiansen O.D. A randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarnage evidence for a therapeutic effect in women with secondry recurrent miscamage. Hum. Reprod. 2002; 17: 809-816.Shoenfeld Y., Kutz U. IVIG therapy in autoimmunity and related disorders our experience with a large cohort of patients. Autoimmunity. 2005; 38 (2): 123-137.Shoenfeld Y., Kutz U. IVIG therapy in autoimmunity and related disorders our experience with a large cohort of patients. Autoimmunity. 2005; 38 (2): 123-137.Stricker R.B., Stenleitner A., Winger E.E. Intravenous immunoglobulin therapy for immunologic abortion. Clin. Appl. Rev. 2002; 43: 187-199.Stricker R.B., Stenleitner A., Winger E.E. Intravenous immunoglobulin therapy for immunologic abortion. Clin. Appl. Rev. 2002; 43: 187-199.Stephenson M. Inravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multicentered randomized placebocontrolled trial. M. Stephenson. Hum. Reprod. 2010; 25 (9): 2203-1209.Stephenson M. Inravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multicentered randomized placebocontrolled trial. M. Stephenson. Hum. Reprod. 2010; 25 (9): 2203-1209.Tzronkowski P., Szit E., Mysliwska E. CD4+ CD25+ T-regulatory cells ingibit human cytotoxic activity of CTL and NK-cells in humans – impact of immunosensence. Clin. Immunol. 2006; 119: 307-312.Tzronkowski P., Szit E., Mysliwska E. CD4+ CD25+ T-regulatory cells ingibit human cytotoxic activity of CTL and NK-cells in humans – impact of immunosensence. Clin. Immunol. 2006; 119: 307-312.Triolo G. IVIG in pregnancy. Lupus. 2004; 13 (9): 731-736.Triolo G. IVIG in pregnancy. Lupus. 2004; 13 (9): 731-736.
The authors declare that there are no conflicts of interest present.